Role of polymorphonuclear leukocytes in the resistance of tumor-bearing mice against Candida albicans infection

Yoshio Okawa, Makiko Kobayashi, Kazuhiko Sakai, Masuko Suzuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tumor-bearing mice showed a significant resistance against Candida albicans intravenous infection. Longer survival was observed in groups of mice inoculated with fungal cells 2-3 weeks after tumor transplantation with allogeneic sarcoma 180, syngeneic methylcholanthrene-induced Meth A fibrosarcoma, and MM 46 mammary carcinoma than in non-tumor-bearing mice inoculated only with fungal cells. This effect was not observed when the mice were infected only 1 week after tumor transplantation. A significant decrease in the number of C. albicans cells in the kidneys was observed in mice inoculated with fungal cells 2-3 weeks after tumor transplantation. In the tumor-bearing mice treated with cyclophosphamide (CY), a remarkable decrease in both the number of peripheral blood polymorphonuclear leukocytes (PMNs) and the defense against challenge with C. albicans cells was observed, as compared with the CY-untreated groups (normal and tumor-bearing mice). A marked increase in the calcium concentration in serum and number, candidacidal activity, active oxygen level, and myeloperoxidase activity of PMNs was observed in the 2-3-week tumor-bearing mice. From these results, it is suggested that PMNs, which accumulated in the 2-3-week tumor-bearing mice, play an important role in the protection from C. albicans infection by increasing the number and the types of killing factors.

Original languageEnglish (US)
Pages (from-to)674-678
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume27
Issue number5
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Candida albicans
Neutrophils
Infection
Neoplasms
Cyclophosphamide
Transplantation
Sarcoma 180
Methylcholanthrene
Fibrosarcoma
Homologous Transplantation
Peroxidase
Reactive Oxygen Species
Breast Neoplasms
Calcium
Kidney
Serum

Keywords

  • Candida albicans
  • Killing factor
  • Polymorphonuclear leukocyte
  • Protection against infection
  • Tumor-bearing mouse

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Role of polymorphonuclear leukocytes in the resistance of tumor-bearing mice against Candida albicans infection. / Okawa, Yoshio; Kobayashi, Makiko; Sakai, Kazuhiko; Suzuki, Masuko.

In: Biological and Pharmaceutical Bulletin, Vol. 27, No. 5, 05.2004, p. 674-678.

Research output: Contribution to journalArticle

Okawa, Yoshio ; Kobayashi, Makiko ; Sakai, Kazuhiko ; Suzuki, Masuko. / Role of polymorphonuclear leukocytes in the resistance of tumor-bearing mice against Candida albicans infection. In: Biological and Pharmaceutical Bulletin. 2004 ; Vol. 27, No. 5. pp. 674-678.
@article{46c15441100f4a17a87c8c519c7e3597,
title = "Role of polymorphonuclear leukocytes in the resistance of tumor-bearing mice against Candida albicans infection",
abstract = "Tumor-bearing mice showed a significant resistance against Candida albicans intravenous infection. Longer survival was observed in groups of mice inoculated with fungal cells 2-3 weeks after tumor transplantation with allogeneic sarcoma 180, syngeneic methylcholanthrene-induced Meth A fibrosarcoma, and MM 46 mammary carcinoma than in non-tumor-bearing mice inoculated only with fungal cells. This effect was not observed when the mice were infected only 1 week after tumor transplantation. A significant decrease in the number of C. albicans cells in the kidneys was observed in mice inoculated with fungal cells 2-3 weeks after tumor transplantation. In the tumor-bearing mice treated with cyclophosphamide (CY), a remarkable decrease in both the number of peripheral blood polymorphonuclear leukocytes (PMNs) and the defense against challenge with C. albicans cells was observed, as compared with the CY-untreated groups (normal and tumor-bearing mice). A marked increase in the calcium concentration in serum and number, candidacidal activity, active oxygen level, and myeloperoxidase activity of PMNs was observed in the 2-3-week tumor-bearing mice. From these results, it is suggested that PMNs, which accumulated in the 2-3-week tumor-bearing mice, play an important role in the protection from C. albicans infection by increasing the number and the types of killing factors.",
keywords = "Candida albicans, Killing factor, Polymorphonuclear leukocyte, Protection against infection, Tumor-bearing mouse",
author = "Yoshio Okawa and Makiko Kobayashi and Kazuhiko Sakai and Masuko Suzuki",
year = "2004",
month = "5",
doi = "10.1248/bpb.27.674",
language = "English (US)",
volume = "27",
pages = "674--678",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "5",

}

TY - JOUR

T1 - Role of polymorphonuclear leukocytes in the resistance of tumor-bearing mice against Candida albicans infection

AU - Okawa, Yoshio

AU - Kobayashi, Makiko

AU - Sakai, Kazuhiko

AU - Suzuki, Masuko

PY - 2004/5

Y1 - 2004/5

N2 - Tumor-bearing mice showed a significant resistance against Candida albicans intravenous infection. Longer survival was observed in groups of mice inoculated with fungal cells 2-3 weeks after tumor transplantation with allogeneic sarcoma 180, syngeneic methylcholanthrene-induced Meth A fibrosarcoma, and MM 46 mammary carcinoma than in non-tumor-bearing mice inoculated only with fungal cells. This effect was not observed when the mice were infected only 1 week after tumor transplantation. A significant decrease in the number of C. albicans cells in the kidneys was observed in mice inoculated with fungal cells 2-3 weeks after tumor transplantation. In the tumor-bearing mice treated with cyclophosphamide (CY), a remarkable decrease in both the number of peripheral blood polymorphonuclear leukocytes (PMNs) and the defense against challenge with C. albicans cells was observed, as compared with the CY-untreated groups (normal and tumor-bearing mice). A marked increase in the calcium concentration in serum and number, candidacidal activity, active oxygen level, and myeloperoxidase activity of PMNs was observed in the 2-3-week tumor-bearing mice. From these results, it is suggested that PMNs, which accumulated in the 2-3-week tumor-bearing mice, play an important role in the protection from C. albicans infection by increasing the number and the types of killing factors.

AB - Tumor-bearing mice showed a significant resistance against Candida albicans intravenous infection. Longer survival was observed in groups of mice inoculated with fungal cells 2-3 weeks after tumor transplantation with allogeneic sarcoma 180, syngeneic methylcholanthrene-induced Meth A fibrosarcoma, and MM 46 mammary carcinoma than in non-tumor-bearing mice inoculated only with fungal cells. This effect was not observed when the mice were infected only 1 week after tumor transplantation. A significant decrease in the number of C. albicans cells in the kidneys was observed in mice inoculated with fungal cells 2-3 weeks after tumor transplantation. In the tumor-bearing mice treated with cyclophosphamide (CY), a remarkable decrease in both the number of peripheral blood polymorphonuclear leukocytes (PMNs) and the defense against challenge with C. albicans cells was observed, as compared with the CY-untreated groups (normal and tumor-bearing mice). A marked increase in the calcium concentration in serum and number, candidacidal activity, active oxygen level, and myeloperoxidase activity of PMNs was observed in the 2-3-week tumor-bearing mice. From these results, it is suggested that PMNs, which accumulated in the 2-3-week tumor-bearing mice, play an important role in the protection from C. albicans infection by increasing the number and the types of killing factors.

KW - Candida albicans

KW - Killing factor

KW - Polymorphonuclear leukocyte

KW - Protection against infection

KW - Tumor-bearing mouse

UR - http://www.scopus.com/inward/record.url?scp=16644387116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644387116&partnerID=8YFLogxK

U2 - 10.1248/bpb.27.674

DO - 10.1248/bpb.27.674

M3 - Article

C2 - 15133243

AN - SCOPUS:16644387116

VL - 27

SP - 674

EP - 678

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 5

ER -